keyword
MENU ▼
Read by QxMD icon Read
search

Agoraphobia pharmacotherapy

keyword
https://www.readbyqxmd.com/read/27071857/psychological-therapies-for-panic-disorder-with-or-without-agoraphobia-in-adults-a-network-meta-analysis
#1
REVIEW
Alessandro Pompoli, Toshi A Furukawa, Hissei Imai, Aran Tajika, Orestis Efthimiou, Georgia Salanti
BACKGROUND: Panic disorder is characterised by the presence of recurrent unexpected panic attacks, discrete periods of fear or anxiety that have a rapid onset and include symptoms such as racing heart, chest pain, sweating and shaking. Panic disorder is common in the general population, with a lifetime prevalence of 1% to 4%. A previous Cochrane meta-analysis suggested that psychological therapy (either alone or combined with pharmacotherapy) can be chosen as a first-line treatment for panic disorder with or without agoraphobia...
2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26978049/-current-possibilities-in-pharmacotherapy-of-anxiety-disorders-in-children-and-adolescents
#2
RANDOMIZED CONTROLLED TRIAL
N N Zavadenko, N V Simashkova, I N Vakula, N Yu Suvorinova, E E Balakireva, M V Lobacheva
OBJECTIVE: To assess the efficacy and safety of children tenoten in the treatment of children and adolescents with anxiety disorders. MATERIAL AND METHODS: It was conducted a multicenter, double-blind, placebo-controlled trial of the drug tenoten children at a dose of 1 tablet 3 times a day for 12 weeks. The study included 98 patients (boys and girls from 5 to 15 years with a confirmed diagnosis of anxiety disorder), randomized into two groups: the first included 48 patients treated tenotenom children, in the second - 50 patients receiving placebo...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/26837851/facing-the-fear-clinical-and-neural-effects-of-cognitive-behavioural-and-pharmacotherapy-in-panic-disorder-with-agoraphobia
#3
Carolin Liebscher, André Wittmann, Johanna Gechter, Florian Schlagenhauf, Ulrike Lueken, Jens Plag, Benjamin Straube, Bettina Pfleiderer, Lydia Fehm, Alexander L Gerlach, Tilo Kircher, Thomas Fydrich, Jürgen Deckert, Hans-Ulrich Wittchen, Andreas Heinz, Volker Arolt, Andreas Ströhle
INTRODUCTION: Cognitive behavioural therapy (CBT) and pharmacological treatment with selective serotonin or serotonin-noradrenalin reuptake inhibitors (SSRI/SSNRI) are regarded as efficacious treatments for panic disorder with agoraphobia (PD/AG). However, little is known about treatment-specific effects on symptoms and neurofunctional correlates. EXPERIMENTAL PROCEDURES: We used a comparative design with PD/AG patients receiving either two types of CBT (therapist-guided (n=29) or non-guided exposure (n=22)) or pharmacological treatment (SSRI/SSNRI; n=28) as well as a wait-list control group (WL; n=15) to investigate differential treatment effects in general aspects of fear and depression (Hamilton Anxiety Rating Scale HAM-A and Beck Depression Inventory BDI), disorder-specific symptoms (Mobility Inventory MI, Panic and Agoraphobia Scale subscale panic attacks PAS-panic, Anxiety Sensitivity Index ASI, rating of agoraphobic stimuli) and neurofunctional substrates during symptom provocation (Westphal-Paradigm) using functional magnetic resonance imaging (fMRI)...
March 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/26663632/second-stage-treatments-for-relative-nonresponders-to-cognitive-behavioral-therapy-cbt-for-panic-disorder-with-or-without-agoraphobia-continued-cbt-versus-ssri-a-randomized-controlled-trial
#4
Laura A Payne, Kamila S White, Matthew W Gallagher, Scott W Woods, M Katherine Shear, Jack M Gorman, Todd J Farchione, David H Barlow
BACKGROUND: Cognitive behavioral therapy (CBT) and pharmacotherapy are efficacious for the short-term treatment of panic disorder. Less is known about the efficacy of these therapies for individuals who do not respond fully to short-term CBT. METHOD: The current trial is a second-step stratified randomized design comparing two treatment conditions-selective serotonin reuptake inhibitor (SSRI; paroxetine or citalopram; n = 34) and continued CBT (n = 24)-in a sample of individuals classified as treatment nonresponders to an initial course of CBT for panic disorder...
May 2016: Depression and Anxiety
https://www.readbyqxmd.com/read/25395972/clinical-characteristics-of-the-respiratory-subtype-in-panic-disorder-patients
#5
Hye-Min Song, Ji-Hae Kim, Jung-Yoon Heo, Bum-Hee Yu
OBJECTIVE: Panic disorder has been suggested to be divided into the respiratory and non-respiratory subtypes in terms of its clinical presentations. The present study aimed to investigate whether there are any differences in treatment response and clinical characteristics between the respiratory and non-respiratory subtypes of panic disorder patients. METHODS: Among the 48 patients those who completed the study, 25 panic disorder patients were classified as the respiratory subtype, whereas 23 panic disorder patients were classified as the non-respiratory subtype...
October 2014: Psychiatry Investigation
https://www.readbyqxmd.com/read/25138725/the-diagnosis-of-and-treatment-recommendations-for-anxiety-disorders
#6
REVIEW
Borwin Bandelow, Thomas Lichte, Sebastian Rudolf, Jörg Wiltink, Manfred E Beutel
BACKGROUND: Anxiety disorders (panic disorder/agoraphobia, generalized anxiety disorder, social phobia, and specific phobias) are the most common mental illnesses. For example, the 12-month prevalence of panic disorder/agoraphobia is 6%. METHOD: This guideline is based on controlled trials of psychotherapy and pharmacotherapy, retrieved by a systematic search for original articles that were published up to 1 July 2013. Experts from 20 specialty societies and other organizations evaluated the evidence for each treatment option from all available randomized clinical trials and from a synthesis of the recommendations of already existing international and German guidelines...
July 7, 2014: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/24921696/paroxetine-in-panic-disorder-with-agoraphobia
#7
L P Kasper
A case of a panic disorder patient treated successfully in the long term with a selective serotonin re-uptake inhibitor, paroxetine, is reported. Based on this case, the relationship between pharmacotherapy and psychotherapy is discussed.
2001: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/24190762/adequacy-of-treatment-received-by-primary-care-patients-with-anxiety-disorders
#8
Risa B Weisberg, Courtney Beard, Ethan Moitra, Ingrid Dyck, Martin B Keller
BACKGROUND: We examined the adequacy of pharmacotherapy and psychotherapy received by primary care patients with anxiety disorders over up to 5 years of follow-up. METHOD: Five hundred thirty-four primary care patients at 15 US sites, who screened positive for anxiety symptoms, were assessed for anxiety disorders. Those meeting anxiety disorder criteria were offered participation and interviewed again at six and 12 months postintake, and yearly thereafter for up to 5 years...
May 2014: Depression and Anxiety
https://www.readbyqxmd.com/read/23834587/cost-effectiveness-of-cbt-ssri-and-cbt-ssri-in-the-treatment-for-panic-disorder
#9
RANDOMIZED CONTROLLED TRIAL
F J van Apeldoorn, A D Stant, W J P J van Hout, P P A Mersch, J A den Boer
OBJECTIVE: The objective of this study was to assess the cost-effectiveness of three empirically supported treatments for panic disorder with or without agoraphobia: cognitive behavioral therapy (CBT), pharmacotherapy using a selective serotonin reuptake inhibitor (SSRI), or the combination of both (CBT+SSRI). METHOD: Cost-effectiveness was examined based on the data from a multicenter randomized controlled trial. The Hamilton Anxiety Rating Scale was selected as a primary health outcome measure...
April 2014: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/22708267/-jsnp-excellent-presentation-award-for-ascnp-2011-an-analysis-of-pharmacotherapy-combined-cognitive-behavioral-group-therapy-for-panic-disorder-with-agoraphobia
#10
O Takashio, Y Kokubo, R Akita, H Tanaka, K Sakagami, H Shimizu, Y Okajima, D Nakamura, N Akashi, N Kato
No abstract text is available yet for this article.
April 2012: Nihon Shinkei Seishin Yakurigaku Zasshi, Japanese Journal of Psychopharmacology
https://www.readbyqxmd.com/read/22455835/does-anti-obsessional-pharmacotherapy-treat-so-called-comorbid-depressive-and-anxiety-states
#11
RANDOMIZED CONTROLLED TRIAL
Carolina Valerio, Juliana Belo Diniz, Victor Fossaluza, Maria Alice de Mathis, Cristina Belotto-Silva, Marinês Alves Joaquim, Eurípedes Constantino Miguel Filho, Roseli Gedanke Shavitt
BACKGROUND: Obsessive-compulsive disorder (OCD) is a chronic condition that normally presents high rates of psychiatric comorbidity. Depression, tic disorders and other anxiety disorders are among the most common comorbidities in OCD adult patients. There is evidence that the higher the number of psychiatric comorbidities, the worse the OCD treatment response. However, little is known about the impact of OCD treatment on the outcome of the psychiatric comorbidities usually present in OCD patients...
July 2012: Journal of Affective Disorders
https://www.readbyqxmd.com/read/22090798/antianxiety-medications-for-the-treatment-of-complex-agoraphobia-pharmacological-interventions-for-a-behavioral-condition
#12
Giampaolo Perna, Silvia Daccò, Roberta Menotti, Daniela Caldirola
BACKGROUND: Although there are controversial issues (the "American view" and the "European view") regarding the construct and definition of agoraphobia (AG), this syndrome is well recognized and it is a burden in the lives of millions of people worldwide. To better clarify the role of drug therapy in AG, the authors summarized and discussed recent evidence on pharmacological treatments, based on clinical trials available from 2000, with the aim of highlighting pharmacotherapies that may improve this complex syndrome...
2011: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/22033867/psychopharmacology-of-anxiety-disorders
#13
Giovanni B Cassano, Nicolò Baldini Rossi, Stefano Pini
Exposure of the general population to a 1:4 lifetime risk of disabling anxiety has inspired generations of fundamental and clinical psychopharmacologists, from the era of the earliest benzodiazepines (BZ) to that of the selective serotonin reuptake inhibitors (SSRIs) and related compounds, eg, the serotonin and norepinephrine reuptake inhibitors (SNRIs). This comprehensive practical review summarizes current therapeutic research across the spectrum of individual disorders: generalized anxiety disorder (GAD), panic disorder (PD) and agoraphobia (social anxiety disorder), compulsive disorder (OCD), phobic disorder (including social phobia), and posttraumatic stress disorder (PTSD)...
September 2002: Dialogues in Clinical Neuroscience
https://www.readbyqxmd.com/read/21914611/evaluation-of-cognitive-analytic-therapy-cat-outcome-in-patients-with-panic-disorder
#14
P Tzouramanis, A Adamopoulou, V Bozikas, M Voikli, C Zagora, M Lombtzianidou, E Mamouzelos, G Garyfallos
Two categories of treatment have been shown to be effective in treating panic disorder with or without agoraphobia. One is pharmacotherapy using antidepressants and benzodiazepinesand the other is psychotherapy. The present study aims at the assessment of the outcome of Cognitive-Analytic Therapy (CAT), a type of brief psychotherapy, in a sample of 128 psychiatricoutpatients with DSM-IV diagnosis of panic disorder, who attended the Mental Health Center of Northwestern District of Thessaloniki. For this purpose, validated instruments for the evaluation,such as the Minnesota Multiphasic Personality Inventory (MMPI), the Beck Depression Inventory (BDI), the State-Trait Anxiety Inventory (STAI) and the Post-therapy Questionnaire (PtQ), were used...
October 2010: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/21688171/determinants-of-pharmacodynamic-trajectory-of-the-therapeutic-response-to-paroxetine-in-japanese-patients-with-panic-disorder
#15
Shin Ishiguro, Takashi Watanabe, Mikito Ueda, Yoshinori Saeki, Yuki Hayashi, Kazufumi Akiyama, Atsushi Saito, Kazuko Kato, Yoshimasa Inoue, Kazutaka Shimoda
PURPOSE: The objective of this study was to evaluate genetic and pharmacokinetic factors to establish the pharmacotherapeutic effect of paroxetine (PAX) in patients with panic disorder (PD). METHOD: Subjects were 65 drug-naïve patients who fulfilled the DSM-IV-TR criteria for PD diagnosis. All subjects were administered PAX (10 mg/day) for 4 weeks, and PD severity was assessed using the Panic and Agoraphobia Scale (PAS) at baseline and at 2 and 4 weeks after initiation of treatment...
December 2011: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/21683174/comorbidities-and-factors-related-to-discontinuation-of-pharmacotherapy-among-outpatients-with-major-depressive-disorder
#16
Ching-I Hung, Shuu-Jiun Wang, Chia-Yih Liu, Shih-Chieh Hsu, Ching-Hui Yang
OBJECTIVE: Although many studies have researched adherence to pharmacotherapy among patients with major depressive disorder (MDD), the effects of chronic depression, anxiety comorbidities, migraine, and other factors on adherence have rarely been studied. This study investigated which comorbidities and factors independently predicted discontinuation of pharmacotherapy among psychiatric outpatients with MDD. METHODS: One hundred thirty-five subjects (34 men, 101 women) with MDD were enrolled...
July 2011: Comprehensive Psychiatry
https://www.readbyqxmd.com/read/21248950/social-phobias-behavioural-and-pharmacotherapy
#17
R T Reesal, H Bajramovic
Five to 10% of the general population suffers from symptoms of an anxiety disorder. Social phobias, while less common than panic disorder, agoraphobia or simple phobias, are just as debilitating. Patients present with somatic, behavioural, mood and cognitive disturbances, of which unrecognized social isolation, depression, loss of employment, and drug and alcohol abuse can be the result. A symptomatic approach can be implemented through the use of education, insight, support, behaviour therapy, cognitive therapy, and pharmacological intervention...
May 1989: Canadian Family Physician Médecin de Famille Canadien
https://www.readbyqxmd.com/read/20546930/high-prevalence-of-comorbidity-of-migraine-in-outpatients-with-panic-disorder-and-effectiveness-of-psychopharmacotherapy-for-both-disorders-a-retrospective-open-label-study
#18
Kazuo Yamada, Kumi Moriwaki, Hiroaki Oiso, Jun Ishigooka
We investigated the comorbidity rate of migraine in outpatients with panic disorder, and the efficacy of pharmacotherapy for both disorders. Fifty-four patients who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for panic disorder were recruited in the study. Forty-three patients were female, and their age ranged from 20 to 71 (38.8±11.2; mean±S.D.) years. Forty-one patients had agoraphobia. In these patients, we diagnosed migraine and other types of headache, using the International Classification of Headache Disorders, Second Edition (ICHD-II)...
January 30, 2011: Psychiatry Research
https://www.readbyqxmd.com/read/20492852/a-randomized-trial-of-cognitive-behavioral-therapy-or-selective-serotonin-reuptake-inhibitor-or-both-combined-for-panic-disorder-with-or-without-agoraphobia-treatment-results-through-1-year-follow-up
#19
RANDOMIZED CONTROLLED TRIAL
Franske J van Apeldoorn, Marieke E Timmerman, Peter Paul A Mersch, Wiljo J P J van Hout, Sako Visser, Richard van Dyck, Johan A den Boer
OBJECTIVE: To establish the long-term effectiveness of 3 treatments for DSM-IV panic disorder with or without agoraphobia: cognitive-behavioral therapy (CBT), pharmacotherapy using a selective serotonin reuptake inhibitor (SSRI), or the combination of both (CBT + SSRI). As a secondary objective, the relationship between treatment outcome and 7 predictor variables was investigated. METHOD: Patients were enrolled between April 2001 and September 2003 and were randomly assigned to treatment...
May 2010: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/19811776/efficacy-of-d-cycloserine-for-enhancing-response-to-cognitive-behavior-therapy-for-panic-disorder
#20
RANDOMIZED CONTROLLED TRIAL
Michael W Otto, David F Tolin, Naomi M Simon, Godfrey D Pearlson, Shawnee Basden, Suzanne A Meunier, Stefan G Hofmann, Katherine Eisenmenger, John H Krystal, Mark H Pollack
BACKGROUND: Traditional combination strategies of cognitive-behavior therapy plus pharmacotherapy have met with disappointing results for anxiety disorders. Enhancement of cognitive-behavior therapy with d-cycloserine (DCS) pharmacotherapy represents a novel strategy for improving therapeutic learning from cognitive-behavior therapy that remains untested in panic disorder. METHOD: This is a randomized, double-blind, placebo-controlled augmentation trial examining the addition of isolated doses of 50 mg d-cycloserine or pill placebo to brief exposure-based cognitive-behavior therapy...
February 15, 2010: Biological Psychiatry
keyword
keyword
102714
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"